Escitalopram for Agitation in Alzheimer's Disease
Summary
Agitation is common in Alzheimer's disease (AD), but current indicated medications are associated with risks. There is need for safer yet still effective approaches to manage agitation in AD. The S-CitAD study enrols participants with AD, who have developed verbal or physical agitation or increased purposeless movements that cause distress to the participant and/or their loved ones. Participants will be initially provided a non-medication management approach for agitation, and if this is ineffective, will be considered for treatment with a medication for 12 weeks.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 99
Inclusion criteria:
1. Diagnosis of Alzheimer's disease
2. Moderate to severe agitation
3. Has a family member that knows them and can attend visits
Exclusion criteria:
1. No neurological or psychiatric disorders that may interfere with treatment
2. Residence in a long term acute care facility
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Ramnik Sekhon
Principal investigator:
Zahinoor Ismail
Clinical trial:
Yes
REB-ID:
REB18-0052